Importantly, we found evidence suggesting that the co-administration of pertuzumab with trastuzumab may further heighten the immune activation state at the tumor site, reducing the PD-L1+ immune population and enhancing the ADCC response. The gene discussed is CD274; the disease is neoplasm.